Michael T. Redman, CEO & Board Member
Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006.
Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company.
His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products.
Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is a former member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Masters in Business Administration from the University of Phoenix.
Donald Payne, CPA, MBA, Senior Vice President
Mr. Payne serves as the Senior Vice President of Oncolix. He is responsible for accounting, intellectual property administration and general operations of the Company.
Mr. Payne has held various senior management positions at Nanospectra Biosciences, Sensus Drug Development, LifeCell Corporation, Aprogenex and Entex Energy. His financial experience includes initial public offerings on the New York and American Stock Exchanges and numerous private offerings. He has is a co-author of 9 scientific publications and is a co-inventor of 4 issued or pending patent applications. At Nanospectra, he led the preclinical development and toxicity program, successfully filed an IDE for a cancer therapy, and led the company through its initial pilot human trial.
Mr. Payne received an MBA from Rice University in 1992, a BBA from Texas A&M University in 1976 and is a licensed CPA (Texas, 1978). He also holds various advisory positions to academic and economic development entities.